Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose

Angiolillo, 2007, Variability in individual responsiveness to clopidogrel clinical implications, management, and future perspectives, J Am Coll Cardiol, 49, 1505, 10.1016/j.jacc.2006.11.044

Matetzky, 2004, Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction, Circulation, 109, 3171, 10.1161/01.CIR.0000130846.46168.03

Cuisset, 2006, High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome, J Thromb Haemost, 4, 542, 10.1111/j.1538-7836.2005.01751.x

Buonamici, 2007, Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis, J Am Coll Cardiol, 49, 2312, 10.1016/j.jacc.2007.01.094

Richter, 2004, Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine, J Pharmacol Exp Ther, 308, 189, 10.1124/jpet.103.056127

Lau, 2004, Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance, Circulation, 109, 166, 10.1161/01.CIR.0000112378.09325.F9

Hulot, 2006, Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects, Blood, 108, 2244, 10.1182/blood-2006-04-013052

Frere, 2008, Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome, Am J Cardiol, 101, 1088, 10.1016/j.amjcard.2007.11.065

Trenk, 2008, Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents, J Am Coll Cardiol, 51, 1925, 10.1016/j.jacc.2007.12.056

Collet, 2009, Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study, Lancet, 373, 309, 10.1016/S0140-6736(08)61845-0

Simon, 2009, Genetic determinants of response to clopidogrel and cardiovascular events, N Engl J Med, 360, 363, 10.1056/NEJMoa0808227

Mega, 2009, Cytochrome p-450 polymorphisms and response to clopidogrel, N Engl J Med, 360, 354, 10.1056/NEJMoa0809171

Gilard, 2008, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study, J Am Coll Cardiol, 51, 256, 10.1016/j.jacc.2007.06.064

Lau, 2003, Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction, Circulation, 107, 32, 10.1161/01.CIR.0000047060.60595.CC

Siller-Matula, 2009, Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel, Am Heart J, 157, 148.e1, 10.1016/j.ahj.2008.09.017

Schwarz, 1999, Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets—definition and detection of ticlopidine/clopidogrel effects, Thromb Haemost, 82, 1145, 10.1055/s-0037-1614344

Saw, 2003, Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial, Circulation, 108, 921, 10.1161/01.CIR.0000088780.57432.43

Saw, 2007, Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial, J Am Coll Cardiol, 50, 291, 10.1016/j.jacc.2007.01.097

Juurlink, 2009, A population-based study of the drug interaction between proton pump inhibitors and clopidogrel, CMAJ, 180, 713, 10.1503/cmaj.082001

Ho, 2009, Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome, JAMA, 301, 937, 10.1001/jama.2009.261

Bhatt, 2008, ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents, J Am Coll Cardiol, 52, 1502, 10.1016/j.jacc.2008.08.002